Novartis Oncology
Global pharmaceutical company with capabilities spanning biologics and small-molecule R&D, clinical development, regulatory submissions, and multi-site manufacturing for advanced therapies (including cell, gene and radioligand therapies). Also operates global health and foundation programs focused on access, digital health, data/AI and impact valuation, and runs patient support and community health initiatives in low- and middle-income countries.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Regional commercial manufacturing and supply of autologous CAR-T therapies from approved European sites to support clinical and commercial patients.
Commercial-scale radioligand therapy manufacturing from multiple approved sites with phased capacity ramp-up to support US and EU markets.
Program to supply a defined portfolio of essential medicines at reduced cost to public-sector purchasers in low- and middle-income countries, combined with capacity-building activities.
Community health camps, digital monitoring tools and online services to improve diagnosis, adherence and long-term disease management for people with diabetes.
Community-based hypertension screening, updated local treatment guidelines, healthcare professional training and mobile reminders to improve blood pressure control in urban districts.
Programs focused on applying data, digital platforms and AI to improve global health program design, delivery and evaluation.
Regional commercial manufacturing and supply of autologous CAR-T therapies from approved European sites to support clinical and commercial patients.
Commercial-scale radioligand therapy manufacturing from multiple approved sites with phased capacity ramp-up to support US and EU markets.
Program to supply a defined portfolio of essential medicines at reduced cost to public-sector purchasers in low- and middle-income countries, combined with capacity-building activities.
Community health camps, digital monitoring tools and online services to improve diagnosis, adherence and long-term disease management for people with diabetes.
Community-based hypertension screening, updated local treatment guidelines, healthcare professional training and mobile reminders to improve blood pressure control in urban districts.
Programs focused on applying data, digital platforms and AI to improve global health program design, delivery and evaluation.
Expertise Areas
- CAR-T manufacturing
- Radioligand therapy manufacturing
- Cell and gene therapy development
- Oncology clinical development
Key Technologies
- CAR-T cell therapy manufacturing
- Cell and gene therapy platforms
- Radioligand therapy (Lutetium-177 based)
- Allosteric kinase inhibitors (STAMP/allosteric inhibitors)
News & Updates
Announcement of EMA approvals for two European commercial CAR-T manufacturing sites and expansion of global CAR-T manufacturing footprint.
FDA approval for a US radioligand therapy manufacturing facility and multi-site capacity expansion plans with target annual capacity in 2024+.
FDA accepted NDA and granted Priority Review for an investigational targeted radioligand therapy based on positive Phase III data.
FDA accepted and granted Priority Review to an NDA for a first-in-class STAMP (allosteric) inhibitor for chronic myeloid leukemia, based on Phase I and Phase III data.
Company discontinued a gene therapy development program after an independent DMC concluded futility criteria were met; long-term safety follow-up provided for treated patients.
Announcement of EMA approvals for two European commercial CAR-T manufacturing sites and expansion of global CAR-T manufacturing footprint.
FDA approval for a US radioligand therapy manufacturing facility and multi-site capacity expansion plans with target annual capacity in 2024+.
FDA accepted NDA and granted Priority Review for an investigational targeted radioligand therapy based on positive Phase III data.
FDA accepted and granted Priority Review to an NDA for a first-in-class STAMP (allosteric) inhibitor for chronic myeloid leukemia, based on Phase I and Phase III data.
Company discontinued a gene therapy development program after an independent DMC concluded futility criteria were met; long-term safety follow-up provided for treated patients.